Pfizer presents positive results from phase 3 BASIS study of Hympavzi in adults and adolescents with haemophilia A or B with inhibitors at ASH meeting: New York Tuesday, December ...

HYMPAVZI is currently approved in more than 40 countries for the treatment of eligible patients 12 years of age and older living with hemophilia A without factor VIII inhibitors, or hemophilia B ...

With Qfitlia and Cablivi, Sanofi reaches its fourth and fifth approvals in China this year, following Tzield for stage 2 type ...

Sanofi’s Qfitlia and Cablivi approved in China, expanding care for rare diseasesQfitlia, the first antithrombin-lowering therapy for hemophilia, ...

China NMPA approves Sanofi’s Qfitlia for haemophilia and Cablivi for acquired thrombotic thrombocytopenic purpura: Paris Friday, December 12, 2025, 09:00 Hrs [IST] The National ...

Jeff Schaffnit discusses Sanofi's advancements in BTK inhibitors and promising results for hemophilia A therapies at ASH 2025 ...

Pfizer Inc. (NYSE:PFE) is one of the best pharma stocks to invest in. Pfizer Inc. (NYSE:PFE) announced on December 6 results ...

Pfizer has announced results from its phase 3 BASIS study of Hympavzi (marstacimab), demonstrating its success in reducing ...

Chinese regulator the National Medical Products Administration (NMPA) has approved two innovative medicines for rare hematologic diseases: Qfitlia (fitusiran) for hemophilia and Cablivi (caplacizumab) ...

Pfizer Inc. (NYSE: PFE)today presented results from the Phase 3 BASIS study (NCT03938792) evaluating HYMPAVZI® (marstacimab) for adults and ...

DelveInsight's Hemophilia A Market Insights report includes a comprehensive understanding of current treatment practices, hemophilia A emerging drugs, market share of individual therapies, and current ...

China’s National Medical Products Administration (NMPA) has granted approval for Sanofi’s rare haematologic disease ...